Yantai Rongchang biology engineering co., ltd

Yantai Rongchang Bioengineering Co., Ltd. is a Sino-US joint venture with a total investment of 78 million yuan and an initial investment of 30 million yuan, of which Yantai Rongchang Pharmaceutical Co., Ltd. is the Chinese investor. The company is located in Yantai Economic and Technological Development Zone, Shandong Province. The company is committed to the research, development, production and sales of pharmaceutical biological products and related products. At present, the company is mainly engaged in the research and development of "Taiai", a new genetic engineering drug for immunosuppressants. This is a new recombinant protein, which can effectively block B lymphocyte stimulating factor, and is mainly used to treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, as well as B lymphocyte tumors (lymphoma, B lymphocyte leukemia, myeloma, etc. ), and is applying for national first-class clinical approval of new drugs; And has applied for an international patent and obtained the patent authorization from China.